Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Itaconic Acid as A Differential Transcription Regulator of Apoptosis and Autophagy Pathways Genes: A Rat Adipose Mesenchymal Stem Cells Model.

Tabandeh MR., Soroush F., Dayer D.

Laboratory Study on Chronic Inflammation, published in Cell J (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cell J (2022)
Country
Iran
Reported sample size
—
Source database
PubMed
PMID
36259476
PMCID
PMC9617019
DOI
10.22074/cellj.2022.8320
Citations
1

Abstract (original English)

Objective Itaconate, a novel regulatory immunometabolite, is synthesized by inflammatory macrophage. It acts as an anti-inflammatory mediator and regulates several metabolic and signaling pathways particularly Nrf2 pathway. The immunometabolites can affect the stemness potency, differentiation ability and viability of stem cells, but little is known about the critical function of Itaconate on the stem cell fate. The objective of the present study was to determine the regulatory effects of Itaconic acid on the cell viability and transcription of apoptosis and autophagy pathways genes in the rat adipose derived mesenchymal stem cells (ADMSCs). Materials and methods In this experimental study, the ADMSCs were incubated with 125 μM and 250 μM dimethyl itaconate (DMI) for 24 hours or 48 hours. The expression of apoptosis pathway genes ( Bax, Bcl2, Caspase 3, Fas, Fadd and Caspase 8 ) and autophagy pathway genes ( Atg12, Atg5, Beclin, Lc3b and P62 ) were determined using real time polymerase chain reaction (PCR) assay. Using the ELISA method, cellular level of phospho-NRF2 protein was measured. Results The results indicated that DMI increased the expression of NRF2 protein, altered the expression of some apoptosis genes ( Fadd, Bax and Bcl2 ), and changed the expression of some autophagy related genes ( Lc3b, Becline and P62 ) in ADMSCs. DMI had no obvious effect on the transcription

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research